University of Virginia Health System

IRB-HSR # 13288: A Randomized, Double Masked, Active Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap - Eye in Subjects with Neovascular Age-Related Macular Degeneration

The purpose of this 24 month study is to evaluate the safety, effectiveness and tolerability of an investigational medication, VEGF Trap - Eye in subjects with wet AMD.

Key Eligibility Criteria:

1. At least 50 years of age
2. Confirmed diagnosis of wet-AMD
3. Visual acuity between 20/40 and 20/320
4. Received no prior treatment with anti-VEGF agents (i.e. Lucentis®, Avastin®, Macugen®)

For more information about this study please contact the Clinical Research Coordinator, Kristina Holbrook, at (434) 243-2852 or klh7v@virginia.edu or visit http://www.clinicaltrials.gov/ct2/show/NCT00509795?term=regeneron+amd+view+1&rank=1.

The principal investigator is Brian P. Conway, M.D.

IRB-HSR # 13308: A Phase 3, Randomized, Double-Masked, Parallel-Assignment Study of Intravitreal Bevasiranib Sodium, Administered Every 8 or 12 Weeks as Maintenance Therapy Following Three Injections of Lucentis Compared With Lucentis Monotherapy Every 4 Weeks in Patients with Exudative Age-Related Macular Degeneration (AMD)

The purpose of this 24 month study is to compare the safety and effectiveness of the investigational drug, bevasiranib, given either every 8 weeks or every 12 weeks after an initial pre-treatment with 3 injections of Lucentis® (ranibizumab injection) compared to Lucentis® given every 4 weeks to people with wet AMD.

Key Eligibility Criteria:

1. At least 50 years of age
2. Confirmed diagnosis of wet-AMD
3. Visual acuity between 20/40 and 20/320
4. Received no prior treatment with anti-VEGF agents (i.e. Avastin®, Lucentis®, Macugen®) in the study eye

For more information about this study please contact the Clinical Research Coordinator, Kristina Holbrook, at (434) 243-2852 or klh7v@virginia.edu .

The principal investigator is Brian P. Conway, M.D.